Zenith Drugs Limited (NSE:ZENITHDRUG)
India
· Delayed Price · Currency is INR 68.00
-0.90 (-1.31%)
At close: Jun 27, 2025
Zenith Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2018 - 2019 |
Operating Revenue | 1,316 | 1,145 | 916.55 | 734.02 | 775.14 | Upgrade
|
Other Revenue | -0 | -0 | 0 | 0 | 7.55 | Upgrade
|
| 1,316 | 1,145 | 916.55 | 734.02 | 782.68 | Upgrade
| |
Revenue Growth (YoY) | 14.93% | 24.95% | 24.87% | -6.22% | 49.97% | Upgrade
|
Cost of Revenue | 857.17 | 783.17 | 727.11 | 522.81 | 575.83 | Upgrade
|
Gross Profit | 459.03 | 362.02 | 189.44 | 211.21 | 206.86 | Upgrade
|
Selling, General & Admin | 66 | 52.17 | 38.44 | 36.42 | 48.74 | Upgrade
|
Other Operating Expenses | 213.78 | 210.8 | 82.69 | 104.51 | 87.65 | Upgrade
|
Operating Expenses | 292.81 | 276.02 | 134.39 | 153.09 | 145.58 | Upgrade
|
Operating Income | 166.23 | 86 | 55.05 | 58.12 | 61.27 | Upgrade
|
Interest Expense | -20.01 | -11.48 | -18.18 | -11.46 | -13.12 | Upgrade
|
Interest & Investment Income | 10.83 | 1.6 | 5.22 | 0.61 | - | Upgrade
|
Other Non Operating Income (Expenses) | -9.8 | -10.18 | -2.93 | -1.78 | 0.51 | Upgrade
|
EBT Excluding Unusual Items | 147.25 | 65.95 | 39.17 | 45.49 | 48.67 | Upgrade
|
Gain (Loss) on Sale of Assets | 1.59 | - | - | - | 0.11 | Upgrade
|
Other Unusual Items | -14.4 | - | 4.27 | 0.53 | - | Upgrade
|
Pretax Income | 134.43 | 66.57 | 44.06 | 46.02 | 48.77 | Upgrade
|
Income Tax Expense | 37.96 | 17.76 | 12.77 | 15.73 | 14.77 | Upgrade
|
Earnings From Continuing Operations | 96.47 | 48.8 | 31.29 | 30.29 | 34 | Upgrade
|
Minority Interest in Earnings | -0.54 | 0 | 0.1 | - | - | Upgrade
|
Net Income | 95.93 | 48.81 | 31.38 | 30.29 | 34 | Upgrade
|
Net Income to Common | 95.93 | 48.81 | 31.38 | 30.29 | 34 | Upgrade
|
Net Income Growth | 96.54% | 55.53% | 3.60% | -10.90% | 199.77% | Upgrade
|
Shares Outstanding (Basic) | 17 | 12 | 12 | 12 | 12 | Upgrade
|
Shares Outstanding (Diluted) | 17 | 12 | 12 | 12 | 12 | Upgrade
|
Shares Change (YoY) | 42.91% | - | - | - | - | Upgrade
|
EPS (Basic) | 5.59 | 4.07 | 2.62 | 2.52 | 2.83 | Upgrade
|
EPS (Diluted) | 5.59 | 4.07 | 2.62 | 2.52 | 2.83 | Upgrade
|
EPS Growth | 37.53% | 55.53% | 3.60% | -10.90% | 199.77% | Upgrade
|
Free Cash Flow | -183.4 | -103.43 | -0.89 | -6.72 | -14.54 | Upgrade
|
Free Cash Flow Per Share | -10.70 | -8.62 | -0.07 | -0.56 | -1.21 | Upgrade
|
Dividend Per Share | 0.500 | - | - | - | - | Upgrade
|
Gross Margin | 34.88% | 31.61% | 20.67% | 28.78% | 26.43% | Upgrade
|
Operating Margin | 12.63% | 7.51% | 6.01% | 7.92% | 7.83% | Upgrade
|
Profit Margin | 7.29% | 4.26% | 3.42% | 4.13% | 4.34% | Upgrade
|
Free Cash Flow Margin | -13.93% | -9.03% | -0.10% | -0.92% | -1.86% | Upgrade
|
EBITDA | 179.26 | 99.06 | 68.31 | 70.28 | 70.46 | Upgrade
|
EBITDA Margin | 13.62% | 8.65% | 7.45% | 9.57% | 9.00% | Upgrade
|
D&A For EBITDA | 13.03 | 13.05 | 13.26 | 12.16 | 9.18 | Upgrade
|
EBIT | 166.23 | 86 | 55.05 | 58.12 | 61.27 | Upgrade
|
EBIT Margin | 12.63% | 7.51% | 6.01% | 7.92% | 7.83% | Upgrade
|
Effective Tax Rate | 28.24% | 26.68% | 28.99% | 34.18% | 30.29% | Upgrade
|
Revenue as Reported | 1,337 | 1,158 | 926.66 | 735.16 | 783.35 | Upgrade
|
Advertising Expenses | 3.8 | 1.85 | 1.26 | 1.84 | 3.09 | Upgrade
|
Updated May 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.